XL335

XL335 is an orally bioavailable and potent agonist of the farnesoid X receptor (FXR) with an EC₅₀ value of 4 nM in CV-1 cells transfected with human FXR.¹ It is selective for FXR over a panel of 15 nuclear receptors at concentrations up to 10 μM. XL335 induces expression of mouse intestinal bile acid binding protein (IBABP), human bile salt excretory pump (BSEP), and small heterodimer partner (SHP) genes in reporter gene assays. It also induces a 20-, 13-, and 2-fold increase in mRNA expression for IBABP, BSEP, and SHP, respectively, at a concentration of 1 μM. XL335 (3 mg/kg) reduces plasma cholesterol and triglycerides by 39 and 50%, respectively, and decreases the area of pre-atherosclerotic lesions in LDLR^-/- mice fed a Western diet. It also decreases hepatic fibrosis in a mouse model of non-alcoholic steatohepatitis.²

WARNING This product is not for human or veterinary use.

1. Flatt, B., Martin, R., Wang, T.L., et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. 52(4), 904-907 (2009).

2. Zhang, S., Wang, J., Liu, Q., et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51(2), 380-388 (2009).